SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is seeing intense investor enthusiasm driven by a major breakout in HBM demand and bullish sentiment around its role in the AI data center infrastructure. The community is actively debating the stock's parabolic trajectory and long-term rerating potential as memory supply constraints persist, with many comparing it to other leading semi-conductor plays in the current cycle.

Digi Power X, Inc. is a block chain technology company, which engages in crypto currency mining. It focuses on validation through mining, hosting solutions, and blockchain software solutions. It operates through the following segments: Cryptocurrency Mining, Sales of Energy and Electricity, and Colocation Services. The company was founded on February 18, 2017, and is headquartered in Miami, FL.

Digi Power X Inc. - Ordinary Shares (Sub voting)

Digi Power X is trending following a massive $1.1 billion contract with Cerebras Systems for a 40MW AI data center, sparking intense community debate over its long-term valuation versus the potential impact of share dilution. Investors are actively tracking high trading volumes and comparing the stock to other AI infrastructure players as they discuss whether this deal serves as a transformative catalyst or a short-term trading opportunity.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending after the company announced a strategic reorganization that will establish Venmo as a standalone business unit, fueling speculation about potential spinoffs or acquisition interest. While investors are actively debating the long-term implications of this structural shift, others are focused on the upcoming earnings report and whether the company can move past the recurring volatility seen in recent quarters.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is experiencing a massive, momentum-driven rally fueled by severe structural NAND flash memory shortages and surging demand for AI data center storage, leading to intense community debate over whether the stock is undergoing a fundamental re-rating or forming a dangerous bubble. Investors are actively discussing the stock's parabolic trajectory and the potential for a share split, while debating the risks of entering at current levels compared to the potential for further upside as memory supply remains constrained through 2028.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing significant market momentum driven by reports that Apple is exploring the company's foundry services for future chip production. While the community remains divided between investors celebrating a parabolic rally and skeptics calling for a correction, the stock continues to be a focal point for AI-linked infrastructure speculation and intense short-squeeze discussions.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Investors are aggressively piling into SOXS as a hedge against the semiconductor sector's parabolic run, with many traders framing the massive rally in chip stocks as a bubble destined for a sharp reversal. The community remains deeply divided, characterized by persistent debate over market manipulation and the sustainability of record highs, while frustrated bears brace for volatility surrounding upcoming high-stakes earnings reports.

AIOS Tech, Inc. is an investment holding company, which engages in the provision of financing solutions to small- and mid-size enterprises. The company was founded on May 29, 2012 and is headquartered in Shanghai, China.

AIOS Tech Inc. - Ordinary Shares - Class A

AIOS Tech Inc.

AIOS is experiencing extreme volatility driven by a recent reverse stock split and a pivot to AI, fueling intense speculation among traders regarding its potential for a parabolic short squeeze. Community sentiment is deeply polarized, with many retail traders chasing the low-float setup for quick gains while others dismiss the move as a classic pump-and-dump cycle typical of heavily indebted micro-cap stocks.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing significant market attention and upward momentum as investors speculate on a potential short squeeze ahead of its upcoming earnings report. The community is actively debating the stock's volatility, focusing on its high short interest and the strategic impact of recent product launches and acquisitions on long-term growth.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is seeing increased buying activity and institutional accumulation as investors look to capitalize on technical support levels and the company's multi-billion dollar share buyback program. While bearish sentiment persists among some traders regarding recent price action, the community is actively debating whether the stock is nearing a bottom or if it will face further consolidation before attempting to reclaim previous highs.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is facing heightened scrutiny from the investment community as shareholders demand clarity on revenue and contract execution ahead of its upcoming earnings report. The discourse centers on skepticism regarding management's communication, comparing it unfavorably to peers, while traders remain hyper-focused on the company's ability to convert recent defense partnerships and production capacity into tangible financial growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eleven ratings firms that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a ho...

Compass Pathways (CMPS) to Release Quarterly Earnings on Thursday

Compass Pathways (NASDAQ:CMPS) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at...

BIT Capital GmbH Raises Stock Holdings in Compass Pathways PLC Sponsored ADR $CMPS

BIT Capital GmbH increased its position in Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) by 2,963.4% during the 4th quarter, according to the company in its most recent Form 13F...

Compass Pathways (NASDAQ:CMPS) Earns "Buy" Rating from HC Wainwright

HC Wainwright reaffirmed a "buy" rating and set a $70.00 price target on shares of Compass Pathways in a report on Tuesday...

FDA Grants Quick Review Psychedelic Drugs, First Approvals Could Come As Soon As Summer

FDA Grants Quick Review Psychedelic Drugs, First Approvals Could Come As Soon As Summer

 The FDA announced new steps to speed up research on psychedelic treatments for serious mental health conditions, following an executive order from President Donald Trump directing agencies to expand...

Compass Pathways (NASDAQ:CMPS) Sees Large Volume Increase  - Here's Why

Compass Pathways (NASDAQ:CMPS) Sees Strong Trading Volume - Here's What Happened...

<ul class="summary-bullets"><li>CMPS stock has gained 41% this week, on track for its best week ever, if gains hold.&nbsp;</li><li>The voucher, aimed at fast-tracking therapies addressing major national health priorities, entitles Compass to enhanced FDA communications and a dramatically shortened review period for COMP360.</li><li>According to data from Koyfin, 11 of the 12 analysts covering CMPS rate it ‘Buy’ or higher, while one rates it ‘Hold.’</li></ul>Shares of Compass Pathways (CMPS ) climbed 5.5% on Friday, adding to a larger rally this week, after the company said that the U.S. Food and Drug Administration granted its synthetic psilocybin formulation the Commissioner's National Priority Voucher for treatment-resistant depression.CMPS stock has gained 45% this week, on track for its best week ever, if gains hold.The voucher, aimed at fast-tracking therapies addressing major national health priorities, entitles Compass to enhanced FDA communications and a dramatically shortened review period for COMP360, as little as 1-2 months after the application is filed.The company said that the agency has granted its rolling application request, allowing it to submit completed sections of its application rather than waiting for every section to be completed before review commences.Compass has conducted two late-stage studies for COMP360, generating data across more than 1000 patients with treatment-resistant depression. COMP360 may demonstrate effects as quickly as within one day after administration, with durability lasting at least through 6 months for those who achieve a clinically meaningful response after one or two doses, Compass said.<h2 class="st-heading-2">Trump’s Push For Psychedelics</h2>President Trump, over the last weekend, signed an executive order directing health agencies to speed up research on drugs like psilocybin and ibogaine.Earlier on Friday, the FDA also stated it will issue national priority vouchers to three companies studying psilocybin for the treatment of treatment-resistant depression and major depressive disorder, and methylone for the treatment of PTSD. However, Compass is the only publicly traded company in the U.S. among the three.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around CMPS stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.A Stocktwits user expressed optimism for a further rally to $11.<stembedurl>https://www.stocktwits.com/texmade2/message/651311854</stembedurl>Another user opined that the market reaction to the priority review voucher announcement “feels too muted.”<stembedurl>https://www.stocktwits.com/ChristopherMcC/message/651309288</stembedurl>A third user termed the stock “super undervalued.”<stembedurl>https://www.stocktwits.com/Millionaire11/message/651299529</stembedurl>According to data from Koyfin, 11 of the 12 analysts covering CMPS rate it ‘Buy’ or higher, while one rates it ‘Hold.’ The stock has a 12-month average price target of $22.08, implying a potential upside of about 141% from the last closing price.On Friday, B. Riley initiated coverage of Compass Pathways with a ‘Buy’ rating and $17 price target. The company is on track to develop the first FDA-approved oral psychedelic drug for treatment-resistant depression, but the stock trades in the bottom percentile of its psychedelic peers, the analyst told investors in a research note.&nbsp;<a href="https://stocktwits.com/symbol/CMPS">CMPS stock</a> has gained 142% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-lidr-stock-surging-today/cZBh9Q3Rec0">LIDR Stock Surges 35% – This Analyst Sees Potential Returns Of 4-5x Over Time</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

CMPS On Track For Best Week Ever On FDA Push For Psychedelics

Compass said on Friday that the FDA has granted its synthetic psilocybin formulation the Commissioner's National Priority Voucher for treatment-resistant depression.

Equity

Compass said on Friday that the FDA has granted its synthetic psilocybin formulation the Commissioner's National Priority Voucher for treatment-resistant depression.


Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug...

Is COMPASS Pathways (CMPS) Outperforming Other Medical Stocks This Year?

Here is how COMPASS Pathways PLC Sponsored ADR (CMPS) and DBV Technologies S.A. (DBVT) have performed compared to their sector so far this year.

<ul class="summary-bullets"><li>The FDA stated that it will issue national priority vouchers to three companies studying psilocybin for the treatment of treatment-resistant depression and major depressive disorder, and methylone for the treatment of PTSD.</li><li>The agency stated that it has also cleared DemeRx NB’s early-stage clinical trial of noribogaine hydrochloride for potential treatment of alcohol use disorder to proceed following an Investigational New Drug submission.</li><li>Compass Pathways announced that it has been awarded a national priority voucher for COMP360, its proprietary formulation of synthetic psilocybin for treatment-resistant depression.</li></ul>The U.S. Food and Drug Administration (FDA) on Friday announced several regulatory actions to accelerate the development of psychedelic treatments aimed at serious mental health issues.The FDA stated that this will increase support for psychedelic-based medicines for the treatment of conditions like post-traumatic stress disorder, treatment-resistant depression, and major depressive disorder.“Under President Trump’s leadership, we are accelerating the research, approval, and responsible access to promising mental health treatments—including psychedelic therapies like ibogaine—to confront our nation’s mental health crisis head-on, especially for our veterans,” said Health and Human Services Secretary Robert F. Kennedy, Jr.This comes after President Trump signed an executive order last week that directed health agencies to speed up research on drugs like psilocybin, MDMA, and ibogaine.Shares of&nbsp;<a href="https://stocktwits.com/symbol/ENVB">Enveric Biosciences Inc.</a> (ENVB) skyrocketed over 62% in Friday morning’s trade, while&nbsp;<a href="https://stocktwits.com/symbol/CMPS">Compass Pathways Plc.</a> (CMPS) and&nbsp;<a href="https://stocktwits.com/symbol/HELP">Helus Pharma Inc.</a> (HELP) and&nbsp;<a href="https://stocktwits.com/symbol/ENVB">Enveric Biosciences Inc.</a> (ENVB) rose between 2% to 3%.<h2 class="st-heading-2">FDA To Issue National Priority Vouchers</h2>The FDA stated that it will issue national priority vouchers to three companies studying psilocybin for the treatment of treatment-resistant depression and major depressive disorder, and methylone for the treatment of PTSD.Compass Pathways announced that it has been awarded a national priority voucher for COMP360, its proprietary formulation of synthetic psilocybin for treatment-resistant depression.The agency stated that it has also cleared an early-stage clinical trial of noribogaine hydrochloride for potential treatment of alcohol use disorder to proceed following an Investigational New Drug (IND) submission.This is the first time the FDA has permitted a U.S.-based clinical study of an ibogaine derivative, enabling the developer of the novel therapy, DemeRx NB, to initiate a Phase 1 trial in a closely monitored clinical setting in the United States.RFK Jr. said the agency will prioritize therapies with Breakthrough Therapy designation, for which early evidence shows meaningful improvement over existing options for serious mental illness.The agency stated that its decision allows the study to proceed and does not mean the drug has been approved or found to be safe or effective. FDA added that it will continue to review data as it becomes available and support efforts to develop new treatments for alcohol use disorder and other mental health conditions.<a href="https://stocktwits.com/symbol/CMPS">CMPS stock</a> is up 36% year-to-date,&nbsp;<a href="https://stocktwits.com/symbol/HELP">HELP stock</a> is down 33%, while&nbsp;<a href="https://stocktwits.com/symbol/ENVB">ENVB stock</a> is up 77%.The AdvisorShares Psychedelics ETF (PSIL) is up 68% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dan-ives-intel-comeback-rocky-balboa-ai-trade-in-third-innings/cZBWzYEReTv">Dan Ives Compares Intel's Comeback To Rocky Balboa, Says AI Trade Is In Its Third Innings — 'You Follow The Capex, That's Where Investors Are'</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

U.S. President Donald Trump signs an executive order on researching the effects of psychedelic drugs in medical treatment for veterans. (Photo by Allison Robbert/For The Washington Post via Getty Images)

FDA Fast-Tracks Psychedelic Research After Trump’s Executive Order — CMPS, HELP Stocks Gain

The FDA stated that this will increase support for psychedelic-based medicines for the treatment of conditions like post-traumatic stress disorder, treatment-resistant depression, and major depressive disorder.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.44	--	--	N/A
Q4 '25	-$0.40	-$1.00	-148.15%	MISSED
Q3 '25	-$0.40	-$1.44	-264.35%	MISSED
Q2 '25	-$0.43	-$0.41	5.38%	BEAT
Q1 '25	-$0.47	-$0.24	48.62%	BEAT

CMPS
COMPASS Pathways

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest CMPS News

CMPSCOMPASS Pathways